CUE-102 for Recurrent Glioblastoma: A Safety Study
Part of Cancer clinical trials.
This study tests an experimental drug, CUE-102, for people with recurrent glioblastoma. It aims to see if the drug is safe and how well it works. You may be eligible if your tumor has come back once, you have a specific genetic marker (HLA-A*0201), and you are not on other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific genetic marker (HLA-A*0201) that must be confirmed by a blood test.
- Your brain tumor (glioblastoma) has come back after initial treatment, and it's the first time it has recurred.
- You've finished radiation and chemotherapy (temozolomide) at least 12 weeks ago.
- You have a good overall health level (Karnofsky score of 70 or higher).
- You are on stable or decreasing doses of steroids, and have had an MRI in the last 2 weeks.
- You are not currently receiving any other treatment for your recurrent tumor, except possibly surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests whether adding the Optune device (a wearable electric field therapy) to standard chemotherapy (temozolomide) and the immunotherapy drug pembrolizumab can help people with newly diagnosed glioblastoma live longer. You may be able to join if you've completed initial radiation and chemo, and have not received certain immunotherapies before.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
This trial tests a new drug called CM93 that targets a specific change (EGFR) in recurrent glioblastoma, a type of brain cancer. The goal is to see if it can slow or stop tumor growth and to find the best dose.
This early study tests whether a device called TheraSphere is safe when delivered into the brain to treat recurrent glioblastoma. It may help patients by trying a targeted treatment approach, while doctors carefully monitor side effects and safety.
This trial tests two new investigational drugs (ABBV-637, ABBV-155) combined with another drug (ERAS-801) for people with glioblastoma. The goal is to see if this combination can shrink the tumor or slow its growth. You need to have a specific genetic marker (EGFR amplification) in your tumor to be eligible.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.